Parent-Provider Intervention for Improving Medication Adherence in Children With Attention Deficit Hyperactivity Disorder

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
New York State Psychiatric Institute
ClinicalTrials.gov Identifier:
NCT00429221
First received: January 30, 2007
Last updated: April 22, 2013
Last verified: April 2013
  Purpose

This three-phase study will develop and test a provider-administered intervention to improve medication adherence and promote sustained medication use among children with ADHD and their caregivers.


Condition Intervention
Attention Deficit Disorder With Hyperactivity
Behavioral: Tailored Medication Messages for Parents

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: ADHD Medication Adherence: A Parent-Provider Intervention Modeled From HIV

Resource links provided by NLM:


Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:
  • Parents' attitudes and beliefs
  • Parents' reported adherence, prescription refill, and side effect information
  • Children's adherence (all measured at Months 1, 3, and 6)

Enrollment: 0
Study Start Date: January 2006
Detailed Description:

Attention deficit hyperactivity disorder (ADHD) is a common childhood behavior disorder that causes impaired functioning in multiple settings, including home, school, and in relationships with peers. Symptoms of ADHD include impulsiveness, hyperactivity, and inattention. Both medications and behavior therapies have been shown to be effective in treating ADHD. It is essential, however, that children take their medication regularly for it to be effective. This three-phase study will develop and test a provider-administered intervention to improve medication adherence and persistence among children with ADHD and their caregivers.

The first phase of this study will gather information about perspectives on ADHD and its treatment by using focus groups and interviews with participating children and their parents. Phase two of the study will gather information on medication adherence and persistence, as well as demographic information. Phase three of the study will involve developing and testing a three part intervention consisting of an ADHD education component, a short survey to help parents identify non-adherence warning signs, and tailored medication messages for parents. After conducting a pilot with five parent-child pairs to assess feasibility and accessibility, all interested doctors at the study site will receive a lecture on evidence-based treatments for ADHD and a supply of parent ADHD education toolkits. Half of the doctors will be randomly assigned to receive additional training on the experimental procedures and to administer the intervention as part of the study. Parent and child participants will be randomly assigned to receive either treatment with a doctor who has been trained on the experimental intervention or treatment as usual. Assessments will take place at the beginning of treatment and 1, 3, and 6 months after the start of treatment. During each assessment, a saliva sample will be collected from the child, and parents will complete several checklists and questionnaires about ADHD treatment and medication adherence.

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

PHASE I:

Inclusion Criteria:

Parent Focus Group Participants:

  • Must be primary caregiver and legal guardian of child (6-10 years) at time of initial ADHD diagnosis
  • Child must have been diagnosed with ADHD within the last 18 months at Schneider Children's Hospital's (SCH) outpatient clinic (co-morbid diagnosis of oppositional defiant disorder [ODD] or conduct disorder [CD] is permitted)

Provider Focus Group Participants:

  • Child psychiatrist employed by North Shore - Long Island Jewish child psychiatry outpatient department
  • Licensed to practice in New York State
  • Has more than 1 year of experience prescribing medication to youth with ADHD

Child Interview Participants:

  • Diagnosis of ADHD (co-morbid diagnosis of ODD, CD, or mood disorder is permitted)
  • Between 6 and 10 years old at time of initial ADHD diagnosis
  • Diagnosis occurred within 18 months prior to study entry at Zucker Hillside Hospital outpatient clinic

Exclusion Criteria:

Parent Focus Group Participants and Child Interview Participants:

  • Child has significant co-morbid medical conditions, such as diabetes, cystic fibrosis, or severe asthma, resulting in more than 2 emergency visits in the last year
  • Child has a co-morbid diagnosis of psychosis, bipolar disorder, or other serious psychiatric condition within 12 months prior to study entry
  • Child has history of psychiatric hospitalization within 12 months prior to study entry
  • Child is receiving treatment in a different setting

PHASE II:

Inclusion Criteria:

  • Primary caregiver and legal guardian of child (6-10 years) at the time of initial ADHD diagnosis
  • Child has been diagnosed with ADHD within the last 18 months at SCH's outpatient clinic

Exclusion Criteria:

  • Parents of children with co-morbid medical conditions other than oppositional defiant disorder (ODD) or conduct disorder (CD)
  • Parents of children with a co-morbid diagnosis of psychosis, bipolar disorder, mental retardation, or other severe mental illness, evidence of mental retardation, or history of psychiatric hospitalization within 12 months prior to study entry
  • Child is receiving treatment in a different setting

PHASE III:

Inclusion Criteria:

  • Medication naïve children with a primary diagnosis of ADHD (co-morbid ODD will be permitted) at the Child Psychiatric Outpatient Department at SCH
  • Parents are the legal guardians
  • Both parents and children willing to sign the informed consent/assent

Exclusion Criteria:

  • Children with co-morbid medical conditions other than ODD
  • Children with a co-morbid diagnosis of psychosis, bipolar disorder, or other serious psychiatric condition, evidence of mental retardation, or history of recent hospitalization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00429221

Sponsors and Collaborators
New York State Psychiatric Institute
Investigators
Principal Investigator: Elizabeth A. Pappadopulos, PhD Columbia University/New York State Psychiatric Institute
  More Information

Publications:
Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00429221     History of Changes
Other Study ID Numbers: #5327, R34MH078700, DAHBR 96-BHA
Study First Received: January 30, 2007
Last Updated: April 22, 2013
Health Authority: United States: Federal Government

Keywords provided by New York State Psychiatric Institute:
ADHD

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Disease
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Pathologic Processes

ClinicalTrials.gov processed this record on October 01, 2014